AstraZeneca’s CEO, a French-born Australian running an Anglo-Swedish company, is betting $50 billion on a strategy of making the US its largest market — while also pouring $15 billion into China. Each ...

AstraZeneca's share price looks anchored to an outdated story — and the latest results suggest the market may be missing something. The post Below £151, here’s why AstraZeneca’s share price looks a ...

China is AstraZeneca's second-largest market after the United States - Copyright AFP/File Jonathan NACKSTRAND China is AstraZeneca's second-largest market after the ...

Goldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral. Analysts led by Rajan Sharma said AstraZeneca is its preferred name in European pharma as ...

AstraZeneca Plc (NASDAQ:AZN) is reportedly reconsidering its planned $578.4 million (450 million pounds) investment in a new vaccine-manufacturing site, a departure from CEO Pascal Soriot‘s previous ...

Note: Articles may be assigned to more than one subject area, as a result the sum of the subject research outputs may not equal the overall research outputs. Identify research insights to guide ...

We recently published a list of 10 Best UK Stocks to Buy According to Billionaires. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best UK ...

Health Canada has approved AstraZeneca's Koselugo for adults with neurofibromatosis type 1 and inoperable plexiform neurofibromas. The US FDA has granted Priority Review to the supplemental ...

LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine research and development, ...

Note: Articles may be assigned to more than one subject area, as a result the sum of the subject research outputs may not equal the overall research outputs. Note: Hover over the donut graph to view ...